Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

 
• By Joseph Haas
3d illustration of red blood cells in the artery
Six partner companies hope to derive a plasma-based COVID therapy from donors who survived the virus

More from COVID-19

More from Scrip